At Travere Therapeutics, their mission is to identify, develop and deliver life-changing therapies to people living with rare diseases.

Biotechnology

Travere Therapeutics

Jula Inrig, M.D., joined Travere Therapeutics in January 2022 as the company’s chief medical officer. In this role, she is responsible for overseeing the company’s medical functions, clinical development, and clinical operations as well as drug safety/pharmacovigilance.

She brings to Travere more than 15 years of expertise in medical oversight, drug development, clinical trial planning and execution as well as global regulatory engagement. Prior to joining Travere, Dr. Inrig served as Global Head of the Renal Center of Excellence at IQVIA. While at IQVIA, Dr. Inrig was instrumental in the design, execution and strategy of clinical trials leading to U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals in autosomal dominant polycystic kidney disease (ADPKD), and diabetic kidney disease. She was also responsible for the execution of more than 45 clinical trials across 50 countries, enrolling over 25,000 patients, including pivotal phase 3 trials in FSGS, IgAN and lupus nephritis. In addition to her roles at IQVIA, Dr. Inrig served as an inaugural member of the board for the Kidney Health Initiative, a public-private partnership with the FDA, founded with the goal of improving the development of therapies for patients with kidney disease. Dr. Inrig has also served in advisory roles for national societies and their guidelines including the American Society of Nephrology, the National Kidney Foundation, and the American Heart Association.

Dr. Inrig is board certified in nephrology and internal medicine and has served on the faculty at the University of California, Irvine, and as an adjunct in the Department of Medicine at the Duke University School of Medicine. Dr. Inrig received her M.D. from Loma Linda University and completed her internal medicine residency, her nephrology fellowship and obtained a Masters of Health Science at Duke University. Dr. Inrig holds a B.A. from California State University, Sacramento.

Jula Inrig

Charlotte Smith serves as the senior vice president of public affairs and is a member of the executive team at Travere Therapeutics. She has twenty years of experience in the healthcare industry as a senior corporate affairs executive focused on internal and external communications, policy and patient advocacy. Throughout her career, she has worked in the UK, Germany and the US, where she currently resides with her husband, Derek, and son, Jackson, in Long Island, New York.

Ms. Smith joined Travere Therapeutics from Pfizer where she most recently led the company’s global network of almost 100 country communicators. Throughout her twelve years at Pfizer, Ms. Smith held roles of increasing levels of responsibility, including leading Pfizer’s corporate affairs function for Rare Disease, as well as teams focused on the Oncology, Inflammation and Immunology, and Hospital and Vaccines businesses. Earlier in her career, Ms. Smith worked for several leading public relations agencies both in the UK, and the US. Charlotte was born and raised in the UK where she graduated from Leeds Metropolitan University with a degree in public relations and German.

Charlotte Smith

Angela Giannantonio is a senior vice president and member of the executive team at Travere Therapeutics. Ms. Giannantonio has more than 15 years of experience in human resources management, with a strong track record of delivering a best-in-class employee experience and keeping patients at the center, while also driving successful growth and innovation across complex and global organizations. Known for her relentless focus on employee experience and engagement, Ms. Giannantonio most recently was the head of human resources for Alexion Rare Disease where she led the company through its integration with AstraZeneca. She previously served as head of human resources for global commercial operations and corporate functions, leading the organization through hyper-growth and a complex pandemic while ensuring high employee engagement and performance worldwide. Earlier in her career, Ms. Giannantonio served in roles of increasing responsibility across the business, including director of human resources. Ms. Giannantonio holds an MBA from Clark University.

Angela Giannantonio

Chris Cline, CFA, is a senior vice president and member of the executive team at Travere Therapeutics. He is responsible for leading the company’s investor and capital markets engagement, as well as the corporate communications strategy. Since joining Travere Therapeutics in 2014, Mr. Cline has helped strengthen the company’s financial foundation through successful equity and debt offerings and led the development of a dynamic corporate communications platform. Prior to Travere Therapeutics, Mr. Cline was a member of the global investor relations group at Elan Corporation, plc., an Ireland-based biotechnology company focused on neuroscience that was acquired by Perrigo Company. Before his time at Elan, Mr. Cline was a financial analyst in the corporate finance group at Phase Forward, a healthcare technology company with a focus on supporting growth through mergers and acquisitions. Mr. Cline is a chartered financial analyst and an active member of the National Investor Relations Institute. He received his BSBA in finance from the Williams College of Business at Xavier University.

Chris Cline

Mr. Logan is a senior vice president and member of the executive team at Travere Therapeutics. He has led corporate development since March 2018. Prior to Travere Therapeutics, he served as a chief business officer at Tracon Pharmaceuticals, an oncology-focused drug development company. At Tracon, Mr. Logan led all strategic, business, and corporate development efforts, including the company’s IPO in January 2015. Before joining Tracon, Mr. Logan held senior corporate development roles at biopharmaceutical companies Bird Rock Bio (formerly RuiYi, Inc.) and Anadys Pharmaceuticals, Inc., before its acquisition by Roche. Prior to these roles, Mr. Logan was a member of the corporate business development group at Eli Lilly and Company.

Mr. Logan served as an officer in the US Naval Nuclear Propulsion Program. He received his bachelor’s of science in chemical engineering from the University of Michigan, and a master’s in business administration from the Kellogg School of Management at Northwestern University.

Casey Logan

William Rote, Ph.D., has served as senior vice president of research and development for Travere Therapeutics since February 2017. He is responsible for the discovery and translational research, regulatory affairs, quality assurance, biometrics, and technical operations including chemistry, manufacturing, and controls (CMC).

Prior to joining Travere Therapeutics, Dr. Rote led clinical development at Ardea Biosciences, a wholly-owned subsidiary of AstraZeneca. In this role, he was responsible for leading all aspects of clinical trial execution and analysis, including clinical operations, data management, and biostatistics. Prior to his role at Ardea, Dr. Rote held numerous positions of increasing responsibility at Amylin, including vice president and site head for R&D. He earned both his doctorate in pharmacology and bachelor’s in pre-medicine from Pennsylvania State University and received postdoctoral training at the University of Michigan.

William Rote

Peter Heerma has served as a chief commercial officer at Travere Therapeutics since October 2019. He is responsible for leading the company’s commercial organization including commercialization strategy for approved products and pre-commercial planning for pipeline programs. He brings more than 20 years of global experience launching best-in-class therapies across therapeutic areas, managing pipeline, and on-market product portfolios, and leading commercial and cross-functional teams at a number of top biopharmaceutical organizations.

Prior to joining Travere Therapeutics, Mr. Heerma served as global product general manager for oncology and cardiovascular products at Amgen where he led four cross-functional global product leadership teams with a revenue base exceeding $7 billion in 2018. He has also held various commercial leadership roles at AbbVie and Abbott Laboratories, most recently serving as AbbVie’s senior director of portfolio strategy for hepatology and nephrology. Prior to that, he served as senior director and asset team lead for HCV, diabetic nephropathy, and neuroscience development projects at AbbVie. While at Abbott Laboratories, Mr. Heerma held the titles of director of the commercial strategy for renal care, international marketing director for Zemplar, business unit manager of hospital products, and product manager for obesity and cardiovascular products.

He holds a Master of Science in European business administration and business law from the Lund University in Sweden and a Bachelor of Science in retail management and marketing from Stenden University in the Netherlands.

Peter Heerma

Eric Dube, Ph.D., is the president and chief executive officer of Travere Therapeutics and serves as a member of the company’s board of directors. He is a results-driven leader who is committed to patients and integrating their perspectives into all aspects of the company’s operations. At Travere Therapeutics, Dr. Dube oversees a global team dedicated to identifying, developing, and delivering life-changing therapies to people living with rare diseases, as well as the advancement of the company’s promising pipeline featuring an innovative product candidate with first-in-class potential. With leadership experience across the United States, Europe, and Japan, Dr. Dube draws upon significant expertise in managing commercial, operations, market access, medical and business development functions.

Prior to joining Travere Therapeutics, Dr. Dube was president and head of North America at ViiV Healthcare, where he led the commercialization of pipeline assets and oversaw the governance of all pricing, strategy, policy, and investment decisions for the company’s North America business. Before joining ViiV, for more than 18 years he worked in roles of increasing leadership at GlaxoSmithKline plc, spanning critical areas, including sales, marketing, market access, medical affairs, compliance, supply chain, and alliance management. During Dr. Dube’s tenure at GSK, he also led the US Oncology and Global Respiratory businesses. He currently serves on the board of trustees for AIDS United, the executive committee of the board of directors for the Biotechnology Innovation Organization (BIO), and the board of directors for Biocom California and Reneo Pharmaceuticals.

Eric Dube

Josef Pelayo-Clariza

Ms. Williams-Brinkley has been a member of the board of directors of Travere Therapeutics, Inc. since 2021. She has served as president of the Kaiser Foundation Health Plan for the Mid-Atlantic States since 2020, overseeing all of Kaiser Permanente’s care delivery and health plan operations in Washington, D.C., and suburban Maryland, Baltimore, and Northern Virginia. Kaiser Permanente’s Mid-Atlantic States region operates 34 medical offices and has 789,030 members. She joined Kaiser Permanente in 2017 as president of Kaiser Foundation Health Plan and Hospitals of the Northwest, in Portland, Oregon. Prior to her roles at Kaiser Permanente, Ms. Williams-Brinkley served as CEO of KentuckyOne Health, Kentucky’s largest integrated health system. KentuckyOne was a division of CommonSpirit Health, one of the nation’s largest nonprofit health systems. Before joining KentuckyOne Health, Ms. Williams-Brinkley served as president and CEO of Carondelet Health Network in Tucson, Arizona, and as president and CEO of Memorial Healthcare System in Chattanooga, Tennessee.

Ms. Williams-Brinkley has repeatedly appeared on Modern Healthcare’s “Top 25 Women in Healthcare” and “Top 25 Minority Executives in Healthcare” lists, and she was named by Modern Healthcare as one of “2020s 100 Most Influential People”. In addition, Ms. Williams-Brinkley has been named one of Becker’s Hospital Review’s “Most Admired CEOs”. Ms. Williams-Brinkley serves on the not-for-profit boards of DePaul University in Chicago, Illinois, and the National Institutes of Health (NIH) in Washington, D.C., as well as on the board of directors of the University of Phoenix. She holds a bachelor’s degree and a master’s of science degree in nursing from DePaul University, and she has an honorary doctoral degree from Spaulding University, Louisville, Ky. Ms. Williams-Brinkley is also a Fellow of the American College of Healthcare Executives (FACHE).

Ruth Williams-Brinkley

Ron Squarer has been a member of the board of directors of Travere Therapeutics, Inc. since 2017. Mr. Squarer has extensive commercial, development, and executive leadership expertise from a career that spans more than two decades in the biopharmaceutical industry. He served as chief executive officer and a member of the board of directors of Array BioPharma, Inc. from 2012 until its acquisition by Pfizer in 2019. Prior to this, Mr. Squarer held positions of increasing responsibility with Hospira Inc., a global pharmaceutical and medical device company, most recently serving as senior vice president, chief commercial officer, where he was responsible for delivering $4 billion in annual revenue. Mr. Squarer joined Hospira from Mayne Pharma, where he served as senior vice president, global corporate and business development when Mayne was sold to Hospira in 2007. Prior to Mayne Pharma, Mr. Squarer held senior management roles at both Pfizer, Inc., and at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) in the US and Europe. He currently serves as a member of the board of directors for Deciphera Pharmaceuticals and as the chairman of the board at ADC Therapeutics. Mr. Squarer holds an MBA from the Kellogg School of Management, Northwestern University, and a bachelor’s degree in biochemistry from the University of California, Berkeley.

Ron Squarer

Sandra Poole has been a member of the board of directors of Travere Therapeutics, Inc. since 2019. She brings to Travere more than 25 years of biotechnology industry experience in manufacturing strategy, including chemistry, manufacturing, and controls (CMC), technical operations, and product development from research through commercialization. Ms. Poole serves as the chief operating officer of Mythic Therapeutics, an early-stage biotechnology company focused on cancer therapies. Before that, she served as the chief operating officer of LogicBio Therapeutics, Inc., a genome editing company, where she was responsible for leading the company’s internal operations, including all technical functions, quality, and regulatory, and supported a successful initial public offering. Prior to LogicBio, Ms. Poole held executive roles of increasing responsibility at ImmunoGen, Inc., a company developing antibody-drug conjugates (ADCs) to treat cancer. While at ImmunoGen, she built technical development and CMC capabilities and built a network of contract manufacturing organizations to manufacture ADCs. Before joining ImmunoGen, Ms. Poole spent more than 15 years in global manufacturing and development leadership positions at Genzyme (now Sanofi Genzyme). Ms. Poole currently serves on the board of directors of ViaCyte, a company focused on regenerative medicine technology to address beta-cell loss in type 1 diabetes. Ms. Poole holds an M.A.Sc. and a B.A.Sc. in chemical engineering from the University of Waterloo (Canada).

Sandra E. Poole

John Orwin has been a member of the board of directors of Travere Therapeutics, Inc. since 2017. Mr. Orwin has cultivated more than 25 years of biopharmaceutical experience during tenures at some of the industry’s leading companies. Currently, Mr. Orwin serves as the president and chief executive officer (CEO) of Atreca, Inc., a biopharmaceutical company focused on developing novel therapeutics based on a deep understanding of the human immune response. Prior to Atreca, Mr. Orwin also served as CEO of Relypsa, and as a director and CEO of Affymax, which was preceded by a tenure as the company’s chief operating officer. In building successful businesses and commercializing a range of blockbuster products, Mr. Orwin has held leadership roles in marketing, sales, and operations for Genentech, Johnson & Johnson, Alza Pharmaceuticals, Sangstat Medical Corporation, Rhone-Poulenc Rorer, and Schering-Plough Corporation. Mr. Orwin is currently a member of the board of directors of Array BioPharma Inc. and Seagen Inc. Mr. Orwin holds a master’s degree in business administration from New York University and a bachelor’s degree from Rutgers, The State University of New Jersey.

John A. Orwin

Jeffrey A. Meckler has been a member of the board of directors of Travere Therapeutics, Inc. since 2014. He brings extensive biopharmaceutical industry experience to Travere and is currently the chief executive officer at Intec Pharma, Ltd. – a clinical-stage biopharmaceutical company focused on developing a proprietary drug delivery solution for key unmet needs. Previously, he served as CEO and a director of Cocrystal Pharma, Inc. a pharmaceutical company focused on the discovery of novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. Earlier in his career, Mr. Meckler was managing director of the Andra Group, a life sciences consulting firm, and acted as a director and interim CEO of Cypress Bioscience Inc. after its acquisition by Royalty Pharma. He has also served as a director of QLT, Inc., ClearFarma USA, Kyalin Bioscience, and Alveolus Inc. Mr. Meckler held a series of positions at Pfizer Inc. in manufacturing systems, market research, business development, strategic planning, and corporate finance, which included playing a significant role in acquisitions and divestitures. Mr. Meckler is the past president and continues to serve on the board of Children of Bellevue, a non-profit organization focused on advocating and developing pediatric programs at Bellevue Hospital Center. Mr. Meckler holds a B.S. in industrial management and M.S. in industrial administration from Carnegie Mellon University’s Tepper School of Business. In addition, Mr. Meckler received a J.D. from Fordham University School of Law.

Jeffrey A. Meckler

Tim Coughlin, CPA, has been a member of the board of directors of Travere Therapeutics, Inc. since 2015. Mr. Coughlin is the former CFO of Neurocrine Biosciences having served there from 2002 to 2018. Mr. Coughlin has developed expertise in corporate accounting, finance, and operations management of companies ranging in size from start-ups through Fortune 500. Prior to Neurocrine, he served as vice president of financial services at CHI, a nationwide integrated healthcare delivery system. From 1989 to 1999, Mr. Coughlin served as a senior manager in the health sciences practice of Ernst & Young and its predecessors. Mr. Coughlin currently serves on the board of directors of aTyr Pharma, Inc., a biopharmaceutical company focused on immunotherapies for cancer and immune disorders, and of Fate Therapeutics, a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells to treat severe, life-threatening diseases. Mr. Coughlin holds a bachelor’s in accounting from Temple University and a master’s in international business from San Diego State University.

Tim Coughlin

Suzanne Bruhn, Ph.D., has been a member of the board of directors of Travere Therapeutics, Inc. since 2020. She brings to the Travere board more than 20 years of biopharmaceutical experience and a proven track record of success in the development and commercialization of therapies for the treatment of serious diseases with significant unmet needs. Dr. Bruhn serves as the president and chief executive officer of biotechnology company Tiaki Therapeutics Inc., where she is responsible for the vision and overall corporate and capital strategy of the company as it develops innovative therapeutics for patients with neurodegenerative diseases. Prior to her role at Tiaki, Dr. Bruhn served as the president and chief executive officer of Proclara Biosciences where she led the company’s strategy to develop novel treatments for neurodegenerative and peripheral protein misfolding diseases. Before joining Proclara, Dr. Bruhn served as president and chief executive officer of Promedior, Inc., where she focused the company’s strategy on clinical-stage development for rare diseases. Earlier in her career, Dr. Bruhn spent 13 years at Shire Human Genetic Therapies, where she held a series of positions of increasing responsibility, including leading global regulatory affairs, strategic planning, and program management. Dr. Bruhn currently serves as an independent director on the boards of clinical-stage biotechnology companies Cerecor, Inc. and Pliant Therapeutics. She holds a bachelor’s degree in chemistry from Iowa State University, a Ph.D. in chemistry from the Massachusetts Institute of Technology, and was a postdoctoral fellow in the Department of Human Genetics at Harvard Medical School.

Suzanne L. Bruhn

Roy Baynes, M.D., Ph.D., has been a member of the board of directors of Travere Therapeutics, Inc. since 2016. Currently, Dr. Baynes is senior vice president of global clinical development at Merck Research Laboratories. Prior to his role at Merck, Dr. Baynes was senior vice president of oncology, inflammation, and respiratory therapeutics at Gilead Sciences, Inc., which was preceded by his service at Amgen, Inc. as vice president of global clinical development and therapeutic area head for hematology/oncology. Before joining Amgen, Dr. Baynes was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, a National Cancer Institute-designated Comprehensive Cancer Center, at Wayne State University. Dr. Baynes has authored more than 150 publications and is a member or fellow of several international medical societies. Dr. Baynes received his medical degree and a doctorate in philosophy from the University of the Witwatersrand in South Africa and completed his medical training in the Department of Hematology and Oncology at Johannesburg Hospital.

Roy D. Baynes

Gary Lyons has been a member of the board of directors of Travere Therapeutics, Inc. since 2014 and assumed the role of chairman in May of 2016. Previously, Mr. Lyons was the founding president and chief executive officer of Neurocrine Biosciences from 1993 to 2008 and remains a member of the board of directors. Prior to his work at Neurocrine, Mr. Lyons held a number of senior management positions at Genentech, Inc., including vice president of business development and vice president of sales. Mr. Lyons currently serves as chairman of the board of directors for Rigel Pharmaceuticals, Inc., a biotechnology company focused on developing drugs for the treatment of inflammatory/autoimmune and metabolic diseases. He also serves as a director for Vical Incorporated, a biotechnology company focused on the prevention and treatment of serious or life-threatening diseases. Mr. Lyons was previously a director of PDL BioPharma, Inc., NeurogesX, Inc., and Facet Biotech Corporation. Mr. Lyons holds a B.S. in marine biology from the University of New Hampshire and an MBA from Northwestern University’s J.L. Kellogg Graduate School of Management.

Gary A. Lyons

Elizabeth Reed serves as senior vice president, general counsel, and corporate secretary of Travere Therapeutics. She has been with the company since January 2017 and is responsible for overseeing the company’s generally legal, intellectual property, government affairs, and corporate compliance functions.

Previously, Ms. Reed served as general counsel of Celladon Corporation, and prior to Celladon, served as general counsel of Anadys Pharmaceuticals, Inc. until Anadys’ acquisition by Roche. Prior to joining Anadys, she was an attorney with the law firms Cooley Godward LLP and Brobeck, Phleger & Harrison LLP. Ms. Reed is a member of the State Bar of California and received her law degree from Harvard Law School and her bachelor’s in business administration from the University of California at Berkeley.

Elizabeth Reed

Laura Clague, CPA, has served as chief financial officer of Travere Therapeutics since November 2014. Ms. Clague has 30 years of experience as a financial executive and oversees the company’s accounting, finance, IT, and facilities functions. Previously, Ms. Clague served as chief financial officer of the San Diego and Ohio operations of Amylin Pharmaceuticals, Inc., after its acquisition by Bristol-Myers Squibb and subsequent divestiture to AstraZeneca. Prior to the acquisition, Ms. Clague was the vice president, corporate controller, and principal accounting officer of Amylin for 10 years, when she also served as the chief financial officer of Amylin’s collaboration with Eli Lilly and Company.

Earlier, Ms. Clague held financial roles at Sony Electronics, Inc., Cubic Corporation, and KPMG. Ms. Clague currently serves on the board of directors of Fluidigm Corporation and Genasys, Inc. Ms. Clague is a certified public accountant in the State of California and received a bachelor’s in business administration from Menlo College.

Leadership Team

About

Team members

Other teams at Travere Therapeutics

Board of Directors

CEO and Executive Team

Discover similar companies